TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30563488

Group type: EXPERIMENTAL
Intervention: Active Schools: Skelmersdale (AS:Sk) multi-component pilot intervention
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Classroom based activities
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Activities outside of the classroom
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Various facilitators identified
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Various barriers identified
Number of subjects: 18
Study: 27548216

Group type: EXPERIMENTAL
Intervention: Interval Sprinting Exercise (ISE)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Green Tea and Interval Sprinting Exercise (GT + ISE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Green Tea (GT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 48
Study: 24060588

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Antidepressant medication (ADM) alone or in combination with CT or IPT
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Combined treatment (ADM + CT or IPT)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Psychotherapy group (CT or IPT)
Number of subjects: 174
Study: 22327475

Group type: EXPERIMENTAL
Intervention: fMRI responses with two cues (binocular disparity and relative motion)
Number of subjects: 0
Study: 20564094

Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg) plus dexamethasone (40 mg)
Number of subjects: 353
Study: 18501073

Group type: EXPERIMENTAL
Intervention: Continuous 5‐FU infusion plus oxaliplatin (n = 23)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Weekly 5‐FU bolus with LV plus oxaliplatin (n = 40)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Oxaliplatin with 2‐day infusion 5‐FU/LV (FOLFOX4, n = 41)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Chronomodulated 5‐FU plus oxaliplatin (n = 25)
Number of subjects: 129
Study: 15941885

Group type: EXPERIMENTAL
Intervention: Ad libitum water consumption
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Total water intake
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Water output through urine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Total water output
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Net water balance
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Total body water (TBW)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Fat-free mass (FFM)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: FFM hydration (TBW:FFM)
Number of subjects: 55
Study: 12812689

Group type: EXPERIMENTAL
Intervention: Individual Education (IE)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Group Education (GE)
Number of subjects: 68
Study: 10565607

Group type: EXPERIMENTAL
Intervention: Profound hypotension induced by enalapril and nitroglycerin for a mean duration of 71 min
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no hypotension induced)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (hypotension and control)
Number of subjects: 21
Study: 8758503

Group type: EXPERIMENTAL
Intervention: Lactulose (20 mg) taken in one intake
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Lactulose (20 mg) taken in two intakes
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Lactulose (20 mg) in both one and two intakes
Number of subjects: 121
Study: 1683179

Group type: EXPERIMENTAL
Intervention: Nizatidine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nizatidine and Ranitidine
Number of subjects: 90
Study: 6110188

Group type: EXPERIMENTAL
Intervention: Dihydergot plus (combination of dihydroergotamine and etilefrine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dihydroergotamine (2 mg, 3 times daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Etilefrine (20 mg, 3 times daily)
Number of subjects: 40
Study: 31047819

Group type: EXPERIMENTAL
Intervention: Combination HAL‐SJ and occupational therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional occupational therapy
Number of subjects: 12
Study: 29050852

Group type: EXPERIMENTAL
Intervention: Sox2/Pax6 dimerization on a DNA library with randomized Pax6 half-site positions
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: ChIP-seq data re-analysis
Number of subjects: 1024
Study: 25723140

Group type: EXPERIMENTAL
Intervention: Maternal ARV treatment
Number of subjects: 2333

Group type: EXPERIMENTAL
Intervention: Maternal LNS/maternal ARV
Number of subjects: 2333

Group type: EXPERIMENTAL
Intervention: Maternal LNS without ARVs
Number of subjects: 2333

Group type: EXPERIMENTAL
Intervention: All interventions in infants
Number of subjects: 2333
Study: 24193176

Group type: EXPERIMENTAL
Intervention: OSTAP block
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAP block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 21689773

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 18922516

Group type: EXPERIMENTAL
Intervention: Relative clause experience
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control experience
Number of subjects: 0
Study: 17499771

Group type: EXPERIMENTAL
Intervention: Entonox
Number of subjects: 61

Group type: COMPARATOR
Intervention: Air
Number of subjects: 61

Group type: COMPARATOR
Intervention: Lidocaine gel
Number of subjects: 61
Study: 15202047

Group type: EXPERIMENTAL
Intervention: Analgesia/sedation (group 2)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (group 3)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No sedation (control group 1)
Number of subjects: 37
Study: 15171770

Group type: EXPERIMENTAL
Intervention: Microporous polysaccharide hemosphere bandage
Number of subjects: 24

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 24
Study: 10509038

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard melphalan and prednisone (MP) chemotherapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) in poor prognosis patients with high LI (>1.2%)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard melphalan and prednisone (MP) chemotherapy in poor prognosis patients with high LI (>1.2%)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) in poor prognosis patients with high β2-M (> 3 mg/L)
Number of subjects: 54
Study: 8949385

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg/day (initial treatment)
Number of subjects: 19193

Group type: EXPERIMENTAL
Intervention: Bitherapy and tritherapy (if necessary)
Number of subjects: 19193

Group type: EXPERIMENTAL
Intervention: Treatment across different geographic areas (Northern Europe vs Southern Europe)
Number of subjects: 19193

Group type: EXPERIMENTAL
Intervention: Treatment across different genders
Number of subjects: 19193

Group type: EXPERIMENTAL
Intervention: Time and number of antihypertensive drugs
Number of subjects: 19193
Study: 1774179

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7340880

Group type: EXPERIMENTAL
Intervention: Cimetidine (1000 mg daily)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cimetidine (1000 mg daily for 5 days)
Number of subjects: 7
Study: 31640241

Group type: EXPERIMENTAL
Intervention: Vitamin D (2800 IU daily)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 29236621

Group type: EXPERIMENTAL
Intervention: Webnovela Mirela (online Spanish-language telenovela)
Number of subjects: 25
Study: 26892413

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise (CPX) test variables
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Peak Vo2 (ml·kg(‐1)·min(‐1))
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Exercise duration
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: %ppVo2
Number of subjects: 2100
Study: 24612478

Group type: EXPERIMENTAL
Intervention: Polyacrylic acid
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Topical testosterone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Topical estrogen
Number of subjects: 80

Group type: COMPARATOR
Intervention: K-Y jelly (placebo lubricant)
Number of subjects: 80
Study: 22450017

Group type: EXPERIMENTAL
Intervention: 12.5 g of lactose in 250 cc water
Number of subjects: 39

Group type: COMPARATOR
Intervention: 12.5 g of maltose in 250 cc water
Number of subjects: 39
Study: 21053622

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 17400977

Group type: EXPERIMENTAL
Intervention: Amiodarone (AMIO) 600 mg orally for seven days before surgery and 45 mg/hr intravenously for 48 hr postoperatively
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amiodarone (AMIO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16290999

Group type: EXPERIMENTAL
Intervention: External loop recorder (1-month duration)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Holter monitor (48-hour duration)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cost per diagnosis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Holter followed by loop recorder strategy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Loop recorder followed by Holter strategy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Incremental cost-effectiveness ratio of loop recorder
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bootstrapping analysis
Number of subjects: 100
Study: 12015692

Group type: EXPERIMENTAL
Intervention: Ertapenem (1 g once daily)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (3.375 g every 6 h)
Number of subjects: 540
Study: 9518998

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 10
Study: 8556971

Group type: EXPERIMENTAL
Intervention: Paroxetine (10, 20, 50 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: d-amphetamine (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31537443

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30619887

Group type: EXPERIMENTAL
Intervention: Low dose carvedilol (3.125 mg twice daily) for 1 week
Number of subjects: 30
Study: 26556616

Group type: EXPERIMENTAL
Intervention: Night shift
Number of subjects: 51
Study: 25458027

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600mg tid
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 22471288

Group type: EXPERIMENTAL
Intervention: Interrogative intention-only condition
Number of subjects: 762

Group type: COMPARATOR
Intervention: Declarative intention-only condition
Number of subjects: 762

Group type: COMPARATOR
Intervention: Interrogative intention + moral norm condition
Number of subjects: 762
Study: 19269519

Group type: EXPERIMENTAL
Intervention: Short-course preoperative radiotherapy (25 Gy in five fractions; n=674)
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Selective postoperative chemoradiotherapy (45 Gy in 25 fractions with concurrent 5-fluorouracil; n=676)
Number of subjects: 1350
Study: 17381256

Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15497611

Group type: EXPERIMENTAL
Intervention: TachoComb
Number of subjects: 55

Group type: COMPARATOR
Intervention: Gas compresses (control)
Number of subjects: 55
Study: 11242378

Group type: EXPERIMENTAL
Intervention: Injection therapy (anesthetics, steroids, or both)
Number of subjects: 21
Study: 9644527

Group type: EXPERIMENTAL
Intervention: 7-day switch therapy with parenteral cefuroxime 750 mg for 3-5 days followed by oral cefuroxime axetil 500 mg every 12 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7-day therapy with parenteral cefuroxime 750 mg every 8 hours
Number of subjects: 0
Study: 8162812

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 57
Study: 2835891

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 120
Study: 29340574

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conscious Sedation (CS)
Number of subjects: 128
Study: 27838347

Group type: EXPERIMENTAL
Intervention: Fluticasone treatment for 6 weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Atopic asthma
Number of subjects: 84

Group type: COMPARATOR
Intervention: Atopy but no asthma
Number of subjects: 84

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 84
Study: 26268314

Group type: EXPERIMENTAL
Intervention: PanAd3‐RSV vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PanAd3‐RSV vaccine in combination with MVA‐RSV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24048694

Group type: EXPERIMENTAL
Intervention: Personal health budgets
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Conventional support arrangements (Control)
Number of subjects: 2000
Study: 21924181

Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 85
Study: 18433614

Group type: EXPERIMENTAL
Intervention: EASI derived ECG
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: GEN derived ECG
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PS derived ECG
Number of subjects: 44
Study: 15668336

Group type: EXPERIMENTAL
Intervention: 2-hydroxyethyl methacrylate (HEMA)
Number of subjects: 0
Study: 12950124

Group type: EXPERIMENTAL
Intervention: Urethral catheterisation (18 patients)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Suprapubic percutaneous cystostomy (17 patients)
Number of subjects: 35
Study: 10391070

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) at a dosage of 4 mg/kg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Transfer Factor (TF) with one unit every third day for the first week, two units per week for the next three weeks, and one monthly unit for six months
Number of subjects: 18
Study: 8748007

Group type: EXPERIMENTAL
Intervention: PLF (cisplatin or carboplatin, leucovorin, and 5-fluorouracil)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PLEF (PLF + etoposide)
Number of subjects: 43
Study: 2050157

Group type: EXPERIMENTAL
Intervention: Metoclopramide cocktail (10 mg/kg) with betamethasone (20 mg) and biperiden (5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dixyrazine combination (240 mg) with betamethasone (20 mg) and biperiden (5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dixyrazine combination (240 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoclopramide cocktail (10 mg/kg)
Number of subjects: 20
Study: 6617071

Group type: EXPERIMENTAL
Intervention: Codeine sulfate, 60 mg
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Codeine sulfate, 120 mg
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Aspirin, 650 mg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 30654835

Group type: EXPERIMENTAL
Intervention: βHB mineral salt
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30409160

Group type: EXPERIMENTAL
Intervention: Gram stain-guided initial antibiotic treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Guidelines-based initial antibiotic treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Gram stain-guided treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Guidelines-based treatment
Number of subjects: 200
Study: 26179655

Group type: EXPERIMENTAL
Intervention: Early Childhood Oral Health Impact Scale (ECOHIS)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: ECOHIS
Number of subjects: 189
Study: 25192851

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg
Number of subjects: 618

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study: 22495093

Group type: EXPERIMENTAL
Intervention: Physio Acoustic Sound (PAS) therapy, applied for 30 minutes on a mattress with an in-built PAS device during the intervention period.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no PAS therapy), measurements continued without intervention during the wash-out period.
Number of subjects: 66
Study: 20104935

Group type: EXPERIMENTAL
Intervention: Eplerenone 25-50 mg/day
Number of subjects: 4265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4265

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 4265
Study: 17604563

Group type: EXPERIMENTAL
Intervention: LA (600 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 14988893

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Restenting (for focal ISR)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Restenting (for diffuse ISR)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Diffuse ISR (as a condition)
Number of subjects: 113
Study: 11224984

Group type: EXPERIMENTAL
Intervention: New approaches to treatment based on immune system recognition of genetic alterations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Understanding of tumor development and genetic alterations
Number of subjects: 0
Study: 9513327

Group type: EXPERIMENTAL
Intervention: Transarterial technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paresthesia technique
Number of subjects: 40
Study: 7999408

Group type: EXPERIMENTAL
Intervention: 0.5 mg fadrozole hydrochloride (CGS 169 49A) twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 mg fadrozole hydrochloride (CGS 169 49A) twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mg fadrozole hydrochloride (CGS 169 49A) twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4 mg fadrozole hydrochloride (CGS 169 49A) daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All doses of fadrozole hydrochloride
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study: 2494079

Group type: EXPERIMENTAL
Intervention: Uchida technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pomeroy technique
Number of subjects: 20
Study: 1101363

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing dentifrices (0.1% and 0.4%)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo dentifrices
Number of subjects: 73
Study: 31897933

Group type: EXPERIMENTAL
Intervention: Rapid ventricular pacing (RVP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no RVP)
Number of subjects: 100
Study: 28776408

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 10 treatments of invisible infrared laser (904 nm, 3 Joules/point) over three weeks followed by an eight-week supervised strengthening exercise program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo LLLT (identical treatment with disabled infrared laser output)
Number of subjects: 40
Study: 26973326

Group type: EXPERIMENTAL
Intervention: Manual therapy with exercise (MT+Ex)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Exercise with boosters (Ex+B)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Exercise without boosters (Ex)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Manual therapy with exercise without boosters (MT+Ex)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Manual therapy with exercise with boosters (MT+Ex+B)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Participants receiving boosters
Number of subjects: 300

Group type: COMPARATOR
Intervention: Participants not receiving boosters
Number of subjects: 300
Study: 25535193

Group type: EXPERIMENTAL
Intervention: Ultrasonically activated scalpel harmonic ACE (Ethicon Endo‐Surgery)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Monopolar coagulation
Number of subjects: 164
Study: 22759542

Group type: EXPERIMENTAL
Intervention: WHO multimodal strategy with ABHR and powdered gloves
Number of subjects: 18669

Group type: EXPERIMENTAL
Intervention: WHO multimodal strategy with ABHR and powderless gloves
Number of subjects: 18669

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18669

Group type: EXPERIMENTAL
Intervention: WHO multimodal strategy
Number of subjects: 18669
Study: 20116457

Group type: EXPERIMENTAL
Intervention: Enhanced Medical Management (EMM; SMM plus individual drug counseling)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard Medical Management (SMM)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (bup/nx)
Number of subjects: 100
Study: 18338152

Group type: EXPERIMENTAL
Intervention: 40 W TULP (2.2 J, 18 Hz)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 25 W TULP (2.0 J, 12 Hz)
Number of subjects: 129

Group type: COMPARATOR
Intervention: HoLEP (high-powered holmium laser enucleation)
Number of subjects: 129

Group type: COMPARATOR
Intervention: TURP (transurethral resection of the prostate)
Number of subjects: 129
Study: 16186674

Group type: EXPERIMENTAL
Intervention: Oral butorphanol 0.2 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral midazolam 0.5 mg/kg
Number of subjects: 60
Study: 14514400

Group type: EXPERIMENTAL
Intervention: rhGH given from 7 - 9 PBD (T1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rhGH given from 10 - 14 PBD (T2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 40
Study: 10663451

Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg as single oral dose at 2200 hours)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No pantoprazole (baseline measurements)
Number of subjects: 6
Study: 8880941

Group type: EXPERIMENTAL
Intervention: 0.3 mg nicotine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.6 mg nicotine
Number of subjects: 36

Group type: COMPARATOR
Intervention: saline
Number of subjects: 36
Study: 2051404

Group type: EXPERIMENTAL
Intervention: Eusol dressings
Number of subjects: 75

Group type: COMPARATOR
Intervention: Silastic foam dressings
Number of subjects: 75